IPO Flurry In 2004? Aspirants Stress Profitability, Economic Upturn As Key
This article was originally published in The Gray Sheet
Executive Summary
Increased access to group purchasing contracts - and a subsequent surge in market share - may provide pulse oximeter developer Masimo with the fiscal confidence to pursue an initial public offering during the second half of the year
You may also be interested in...
Novacept Sellers Benefited By Running IPO, M&A Processes Simultaneously
Novacept cultivated interest among potential acquirers and added value to its eventual $325 mil. selling price by pursuing an IPO while at the same time moving down the merger & acquisition path, according to Piper Jaffray's Jeff Hoffman
Novacept Sellers Benefited By Running IPO, M&A Processes Simultaneously
Novacept cultivated interest among potential acquirers and added value to its eventual $325 mil. selling price by pursuing an IPO while at the same time moving down the merger & acquisition path, according to Piper Jaffray's Jeff Hoffman
Cautious Venture Capital Commands Medtech Start-Ups To Think Long-Term
A growing emphasis on evidence-based medicine is compelling medtech start-ups to seek consultation in developing a reimbursement strategy